Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences. Management will conduct a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET. Additionally, they will participate in 1x1 meetings at the BTIG Virtual Biotechnology Conference 2025, scheduled for July 29-30, 2025. Webcasts and replays will be available on the company's investor relations website for at least 30 days after the events.
Avalo Therapeutics (NASDAQ: AVTX), una società biotecnologica in fase clinica specializzata in trattamenti per la disfunzione immunitaria, ha annunciato la sua partecipazione a due prossimi eventi per investitori. Il management terrà una conversazione informale al HCW Annual Inflammation & Immunology Virtual Conference il 30 giugno 2025 alle 11:00 ET. Inoltre, parteciperà a incontri individuali durante il BTIG Virtual Biotechnology Conference 2025, previsto per il 29-30 luglio 2025. Le dirette streaming e le registrazioni saranno disponibili sul sito web delle relazioni con gli investitori della società per almeno 30 giorni dopo gli eventi.
Avalo Therapeutics (NASDAQ: AVTX), una empresa biotecnológica en etapa clínica especializada en tratamientos para la disfunción inmunitaria, ha anunciado su participación en dos próximas conferencias para inversionistas. La dirección realizará una charla informal en la HCW Annual Inflammation & Immunology Virtual Conference el 30 de junio de 2025 a las 11:00 am ET. Además, participarán en reuniones uno a uno en la BTIG Virtual Biotechnology Conference 2025, programada para el 29 y 30 de julio de 2025. Las transmisiones en vivo y las repeticiones estarán disponibles en el sitio web de relaciones con inversionistas de la compañía por al menos 30 días después de los eventos.
임상 단계의 생명공학 회사인 Avalo Therapeutics(NASDAQ: AVTX)는 면역 조절 치료에 특화되어 있으며, 다가오는 두 개의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 경영진은 2025년 6월 30일 오전 11시(동부시간)에 열리는 HCW 연례 염증 및 면역학 가상 컨퍼런스에서 파이어사이드 채팅을 진행할 예정입니다. 또한, 2025년 7월 29일부터 30일까지 예정된 BTIG 가상 생명공학 컨퍼런스에서 1대1 미팅에 참여할 예정입니다. 웹캐스트와 재방송은 행사 종료 후 최소 30일간 회사 투자자 관계 웹사이트에서 제공될 예정입니다.
Avalo Therapeutics (NASDAQ : AVTX), une entreprise biotechnologique en phase clinique spécialisée dans les traitements des dysfonctionnements immunitaires, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction tiendra une discussion informelle lors de la HCW Annual Inflammation & Immunology Virtual Conference le 30 juin 2025 à 11h00 ET. De plus, elle participera à des réunions individuelles lors de la BTIG Virtual Biotechnology Conference 2025, prévue les 29 et 30 juillet 2025. Les webdiffusions et les rediffusions seront disponibles sur le site des relations investisseurs de la société pendant au moins 30 jours après les événements.
Avalo Therapeutics (NASDAQ: AVTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen von Immunfehlregulation spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management wird am 30. Juni 2025 um 11:00 Uhr ET ein Fireside-Chat auf der HCW Annual Inflammation & Immunology Virtual Conference durchführen. Außerdem werden sie an Einzelgesprächen auf der BTIG Virtual Biotechnology Conference 2025 teilnehmen, die für den 29. bis 30. Juli 2025 geplant ist. Webcasts und Wiederholungen werden für mindestens 30 Tage nach den Veranstaltungen auf der Investor-Relations-Website des Unternehmens verfügbar sein.
Positive
None.
Negative
None.
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:
HCW Annual Inflammation & Immunology Virtual Conference Fireside Chat June 30, 2025, at 11:00 am ET
BTIG Virtual Biotechnology Conference 2025 1x1s July 29-30, 2025
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiries Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793
When is Avalo Therapeutics (AVTX) presenting at the HCW Annual Inflammation Conference 2025?
Avalo Therapeutics will present a fireside chat at the HCW Annual Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:00 am ET.
What investor conferences is AVTX attending in summer 2025?
AVTX is participating in two conferences: the HCW Annual Inflammation & Immunology Virtual Conference on June 30 and the BTIG Virtual Biotechnology Conference on July 29-30, 2025.
Where can I watch Avalo Therapeutics' (AVTX) conference presentations?
The webcasts and replays will be available in the News/Events section of Avalo Therapeutics' investor relations website at https://ir.avalotx.com for at least 30 days.
What is Avalo Therapeutics' main focus as a company?
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
